353 related articles for article (PubMed ID: 9882763)
1. Can a change in screening and prescribing practice reduce the risk of venous thromboembolism in women taking the combined oral contraceptive pill?
Mills A; Wilkinson C; Fotherby K
Br J Fam Plann; 1998 Jan; 23(4):112-5. PubMed ID: 9882763
[TBL] [Abstract][Full Text] [Related]
2. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study.
van Vlijmen EF; Brouwer JL; Veeger NJ; Eskes TK; de Graeff PA; van der Meer J
Arch Intern Med; 2007 Feb; 167(3):282-9. PubMed ID: 17296885
[TBL] [Abstract][Full Text] [Related]
4. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users.
Samuelsson E; Hägg S
Acta Obstet Gynecol Scand; 2004 Jul; 83(7):674-81. PubMed ID: 15225194
[TBL] [Abstract][Full Text] [Related]
5. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene.
Santamaría A; Mateo J; Oliver A; Menéndez B; Souto JC; Borrell M; Soria JM; Tirado I; Fontcuberta J
Haematologica; 2001 Sep; 86(9):965-71. PubMed ID: 11532625
[TBL] [Abstract][Full Text] [Related]
6. Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception.
Cosmi B; Legnani C; Bernardi F; Coccheri S; Palareti G
Arch Intern Med; 2003 May; 163(9):1105-9. PubMed ID: 12742811
[TBL] [Abstract][Full Text] [Related]
7. [Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives].
Bauersachs R; Lindhoff-Last E; Ehrly AM; Kuhl H
Zentralbl Gynakol; 1996; 118(5):262-70. PubMed ID: 8701622
[TBL] [Abstract][Full Text] [Related]
8. Combined hormonal contraception and venous thromboembolism.
Martínez F; Avecilla A
Eur J Contracept Reprod Health Care; 2007 Jun; 12(2):97-106. PubMed ID: 17559006
[TBL] [Abstract][Full Text] [Related]
9. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis.
van Vlijmen EF; Wiewel-Verschueren S; Monster TB; Meijer K
J Thromb Haemost; 2016 Jul; 14(7):1393-403. PubMed ID: 27121914
[TBL] [Abstract][Full Text] [Related]
10. Should patients with venous thromboembolism be screened for thrombophilia?
Dalen JE
Am J Med; 2008 Jun; 121(6):458-63. PubMed ID: 18501222
[TBL] [Abstract][Full Text] [Related]
11. [Venous thromboembolism and combined oral contraceptives. Reported adverse reactions indicate at least similar risk with the most recent contraceptive pills].
Kieler H; Persson I; Odlind V
Lakartidningen; 2003 Sep; 100(39):3050-2. PubMed ID: 14560670
[TBL] [Abstract][Full Text] [Related]
12. Oral contraceptives and venous thromboembolism: consensus conference statement.
Dialogues in Contraception Consensus Conference (1995: Chicago)
Dialogues Contracept; 1996; ():1-8. PubMed ID: 12320455
[TBL] [Abstract][Full Text] [Related]
13. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
Sehovic N; Smith KP
Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.
Sidney S; Petitti DB; Soff GA; Cundiff DL; Tolan KK; Quesenberry CP
Contraception; 2004 Jul; 70(1):3-10. PubMed ID: 15208046
[TBL] [Abstract][Full Text] [Related]
15. [The Bavarian Thromboembolic Risk Cohort Study (BATER). Study protocol, state of the investigation and first results].
Schramm W; Heinemann LA; Spannagl M; Dick A; Assmann A
Dtsch Med Wochenschr; 2000 Jan; 125(1-2):2-6. PubMed ID: 10650817
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptives and thrombotic disease: risk of venous thromboembolism.
Helmerhorst FM; Bloemenkamp KW; Rosendaal FR; Vandenbroucke JP
Thromb Haemost; 1997 Jul; 78(1):327-33. PubMed ID: 9198174
[TBL] [Abstract][Full Text] [Related]
18. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.
Wu O; Robertson L; Twaddle S; Lowe GD; Clark P; Greaves M; Walker ID; Langhorne P; Brenkel I; Regan L; Greer I
Health Technol Assess; 2006 Apr; 10(11):1-110. PubMed ID: 16595080
[TBL] [Abstract][Full Text] [Related]
19. Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications.
De Stefano V; Rossi E; Leone G
Semin Vasc Med; 2003 Feb; 3(1):47-60. PubMed ID: 15199492
[TBL] [Abstract][Full Text] [Related]
20. Is screening for thrombophilia cost-effective?
Wu O; Greer IA
Curr Opin Hematol; 2007 Sep; 14(5):500-3. PubMed ID: 17934357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
